Our Partnership Strategy
We believe that collaboration and strategic partnerships are fundamental to improving business outcomes, and benefit not only us but also our partners. We actively pursue such partnering opportunities on our GMAC platform and pipeline.
Our Current Partners
DyDo Pharma is granted the exclusive right of co-development and co-commercialization of LCAT-GMAC for LCAT deficiency in the Japanese territory.
KYORIN Pharmaceutical is granted the exclusive right of co-development and in-licensing of GLA-GMAC for Fabry disease in the Japanese territory.
Interested in Collaborating with us?
(Director of Bussiness Development Dept. Tetsuya SAITO Ph.D)